Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that Mr. Craig Mull has been named Interim Chief Executive Officer of Cipher, replacing Robert Tessarolo. The...

MISSISSAUGA, Ontario, June 12, 2019 (GLOBE NEWSWIRE) -- Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company"), in accordance with Toronto Stock Exchange requirements, announced today...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced its financial and operating results for the three months ended March 31st, 2019. Unless otherwise noted, all...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q1 2019 financial results conference call on Friday, May 10, 2019. The call will be hosted by...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that Mr. Craig Mull was appointed as a member of the Company's Board of Directors, effective immediately. Mr....

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that Stephen Lemieux, Chief Financial Officer and Secretary of Cipher has resigned to pursue other career...

Canadian product revenue increased 30% to $6.9 million for the year Completed six (6) strategic business transactions enhancing long-term value OAKVILLE, ON, March 19, 2019 /CNW/ - Cipher...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q4 2018 financial results conference call on Tuesday, March 19, 2019. The call will be hosted...

Cipher Pharmaceuticals Inc. (TSX:CPH) today announced that its New Drug Submission ("NDS") for A-101 40% topical solution ("A-101 40%") for the treatment of raised seborrheic keratoses ("SKs") has...

Cipher Pharmaceuticals Inc. (TSX:CPH) today announced that its New Drug Submission ("NDS") for plecanatide for irritable bowel syndrome with constipation ("IBS-C") has been accepted by Health...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that it will host a webcast investor presentation on Tuesday, December 11th at 11:00 AM ET. During the webcast,...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that pharmaceutical industry commercial executive, Michael Milloy, has joined the Company in the position of Vice...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced its financial and operating results for the three and nine months ended September 30th, 2018. Unless otherwise...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced the details of its Q3 2018 financial results conference call on Wednesday, November 7, 2018. The call will be...

Cipher Pharmaceuticals Inc. (TSX:CPH) today announced the Canadian launch of Brinavess® (vernakalant hydrochloride) for the rapid conversion of recent onset atrial fibrillation ("AF"), (an...

Transaction broadens Cipher's Canadian portfolio providing entry into rapidly growing market MISSISSAUGA,ON, Sept. 18, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) today announced it has...

Cipher Pharmaceuticals Inc. (TSX:CPH) today announced it received Health Canada approval of Xydalba™ (dalbavancin hydrochloride), the first and only one-dose treatment option for acute bacterial...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced its financial and operational results for the three and six months ended June 30, 2018. Unless otherwise noted,...

Agreement expanded to include a portfolio of novel isotretinoin products New portfolio royalty extends through December 2024 MISSISSAUGA, ON, July 30, 2018 /CNW/ - Cipher Pharmaceuticals Inc....

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q2 2018 financial results conference call on Friday, August 10, 2018. The call will be hosted...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that pharmaceutical industry medical executive, Dr. Diane Gajewczyk, has joined the Company in the position of...

Effective May 15, 2018, the previously announced acquisition by Cipher Pharmaceuticals Inc. ("Cipher") of the Canadian business portfolio of Cardiome Pharma Corp. ("Cardiome") was completed by way...

Cipher Pharmaceuticals Inc. (TSX:CPH) today announced it has completed its previously announced strategic acquisition of the Canadian business portfolio of Cardiome Pharma Corp. (originally...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company"), in accordance with Toronto Stock Exchange requirements, announced today the voting results for the election of directors at its...

Company announces four transactions year to date adding revenue diversification and growth avenues in new therapeutic categories MISSISSAUGA, ON, May 10, 2018 /CNW/ - Cipher Pharmaceuticals Inc....